In 1971, President Richard Nixon signed the Controlled Substances Act, which banned the use of psychedelics.
At the time, the pharmaceutical industry was about to launch a new slate of antidepressant drugs.
Big Pharma knew these drugs would be a moneymaking machine because patients had to take them every day for the rest of their lives.
The pharmaceutical industry pressured the government to make psychedelic compounds illegal… and then went on a campaign to destroy the indigenous cultures behind many medicines.
The government propaganda campaign against psychedelics became ingrained in the minds of American society. And it led to the misunderstanding and taboo nature of these compounds that persists today.
Thanks to the greed and influence of Big Pharma, many people who suffered from mental illnesses couldn’t legally access the treatment options they deserved for decades.
This injustice also set back years of research, as testing of these compounds was also restricted. Scientists had to wade through a sea of red tape to study the benefits of psychedelic treatments. And they risked jail time if they ran afoul of state or federal laws.
Things have finally started to shift with the advent of the internet and the democratization of information. People are getting empowered to do their own research.
And society realizes it’s not necessarily in the financial interest of pharmaceutical companies to cure disease… but rather, just to treat the symptoms.
And a group of small innovators emerged that started producing plant-based medicines to treat these diseases at their root.
Ironically, today the very same pharmaceutical companies that once suppressed them are now coveting them and targeting them for acquisition… Which only makes our opportunity today even sweeter.
History will look back on this 50-plus-year prohibition on psychedelic compounds as one of the greatest insults to human evolution and mental health.
Only recently, in the crisis and aftereffects of COVID-19, has there been a renaissance in how society thinks about the opportunity for these powerful therapeutic compounds.
And because of interest ramping up, we believe we’re on the cusp of the next revolution to impact a multitrillion-dollar market.
Aren’t Psychedelics Illegal?
Now, it’s true psychedelics can be dangerous if abused. But the same applies to all drugs.
For example, Advil is one of the most dangerous drugs in America – if you take too much of it. And we don’t even need to mention legal substances like cigarettes and alcohol, which kill millions of people each year due to users abusing them.
But when it comes to the medical use of drugs, we shouldn’t necessarily frame the argument around what’s legal or illegal… but how the government classifies a drug.
Let me explain…
Today, the government classifies psychedelics as Schedule 1, which includes marijuana and MDMA (also known as the party drug “ecstasy”).
According to the government, these drugs have a high potential for abuse and no currently accepted medical treatment use in the U.S. (As I’ll show you in a moment, nothing can be further from the truth for psychedelics.)
We believe Schedule III is the category psychedelics belong in and will eventually be reclassified as.
Drugs in this category have medical use… but may lead to moderate or low physical dependence or high psychological dependence.
Schedule III classification would put psychedelic substances in the same category as drugs like Tylenol with codeine, anabolic steroids, and Vicodin. They’d still be regulated… but would also be recognized for their medical benefits.
Here’s why we believe Congress will eventually reschedule psychedelics as Schedule III.
Psychedelic Therapies Are Going Mainstream
Research in psychedelic compounds shows they can treat some of the most severe and expensive medical conditions in the world… And they do it better, faster, and at a fraction of the cost of traditional medicines.
In 2017, the FDA granted “breakthrough therapy” designation to MDMA-assisted psychotherapy for PTSD. (The designation allows companies to speed up development and review of drugs intended to treat a serious condition.) Phase 3 clinical trials should be complete this year, meaning the FDA could approve the treatment as early as 2022.
In 2018, the FDA also granted a “breakthrough therapy” designation to Compass Pathways. The company uses psilocybin (a naturally occurring psychedelic compound found in fungi) for treatment-resistant depression (TRD).
In 2019, the FDA gave the same designation to the Usona Institute, which uses psilocybin to treat major depressive disorder (MDD). The condition causes a persistent feeling of sadness and loss of interest.
Pharma giant Johnson & Johnson recently released its own FDA-approved drug, Spravato, to treat people suffering from depression. It’s a fast-acting nasal spray that uses a chemical cousin of ketamine, the so-called party drug “Special K.”
In 2019, the Department of Veteran Affairs approved the psychedelic ketamine for the treatment of PTSD.
This last development is particularly impactful. Right now, the rate of retired and active-duty military personnel taking their own lives is a staggering 20.6 times per day. This approval could help lower that rate and save thousands of lives.
Former VA secretary Robert Wilkie hailed this milestone:
We’re pleased to be able to expand options for veterans with depression who have not responded to other treatments. It reflects our commitment to seek new ways to provide the best health care available for our nation’s veterans.
And there’s more news of adoption on the regulation front, too. In May 2021, the Texas Senate passed a bipartisan bill allowing a study on psilocybin therapy to treat PTSD in veterans.
So we’re moving toward broader acceptance of psychedelic medicines and therapies. And we believe it’s only a matter of time before they become widespread.
Your Chance to be Early and Right
Psychedelics are helping to solve a global healthcare crisis that costs society an estimated $3 trillion in health expenses and lost productivity.
That’s why Daily editor Teeka Tiwari calls this trend his next “trillion-dollar trade.” And you have a chance to get in early… and position yourself in the right companies.
You see, individual investors have an early advantage over institutions. That’s because institutions have to wait until stocks are large enough to trade on the world’s biggest exchanges.
This gives you the opportunity to get in before the institutions… And puts you way ahead as these companies grow and a flood of money finds its way into this space.
That’s why I joined Teeka and Palm Beach Research Group.
Teeka and I believe certain stocks in this burgeoning market could potentially beat a century’s worth of stock market gains in the next 18 months
By coupling my expertise in the psychedelic space with my background on Wall Street, it’s been easy for me to analyze and select the best-of-breed companies.
And now that I’ve joined Teeka, we plan to bring these life-changing ideas to Main Street. So click here to watch our presentation. You won’t want to miss it.